The expansion will see Hitachi Chemical Advanced Therapeutics Solutions (HCATS) add 49,700 sq. ft. to its contract development and manufacturing organisation’s (CDMO) branch, PCT.
The site will house manufacturing development labs, quality control and microbiology labs, additional Grade B/ISO 7 cleanrooms, warehousing and office space.
Validation for the facility is planned before the end of 2018.
The firm said it expects the expansion to attract new business to PCT.
“HCATS anticipates that the increase in demand for cell therapy development and manufacturing services will result in substantial growth of the company’s employee base in the company year,” said the company.
Pearl Court & Yokohama upgrades
The firm also announced plans to upgrade its Pearl Court site in Allendale, and said its regenerative cell-focused CDMO site in Yokohama, Japan, which is under construction, will be validated by April, 2018.
Hitachi Chemical Co. America – the US off-shoot of Japan-based Hitachi Chemical – purchased PTC from majority shareholder Caladrius Biosciences earlier this year.